A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
← catalyst calendarNCT06973187 · readout in 607 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
500estimated
Sites
204
Countries
Argentina, Australia, Austria +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-04 | actual | When the study began enrolling |
| Primary completion | 2028-04-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
- Drug: BGB-16673
- Drug: Pirtobrutinib — also filed as Jaypirca
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) per Independent Review Committee (IRC)
measured Up to approximately 3 years
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed